HC Wainwright & Co. Maintains Buy on Legend Biotech, Raises Price Target to $87
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has reaffirmed a Buy rating on Legend Biotech (NASDAQ:LEGN) and increased the price target from $86 to $87.
November 15, 2023 | 12:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Legend Biotech's stock may see a positive impact in the short term due to the maintained Buy rating and raised price target from $86 to $87 by HC Wainwright & Co.
Analyst ratings and price target adjustments can influence investor sentiment and stock prices. The increase in price target by HC Wainwright & Co. suggests a bullish outlook on Legend Biotech, which could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100